- Home
- GENC vs ELDN Comparison
GENC vs ELDN Comparison
Compare GENC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | ELDN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 166.4M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GENC | ELDN |
|---|---|---|
| Price | $15.14 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $8.50 |
| AVG Volume (30 Days) | 25.3K | ★ 503.0K |
| Earning Date | 05-17-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 54.27 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $125,306.93 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $66.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.80 | $1.35 |
| 52 Week High | $17.40 | $4.60 |
Technical Indicators
Market Signals| Indicator | GENC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 55.90 |
| Support Level | $14.94 | $1.96 |
| Resistance Level | $16.00 | $2.21 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 68.84 | 52.00 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.